239 related articles for article (PubMed ID: 26300931)
21. The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma.
Tran VT; Phan TT; Nguyen TB; Le TT; Tran TT; Nguyen AT; Nguyen HT; Nguyen NB; Ho TT; Pho SP; Nguyen TT; Nguyen HT; Mai HT; Pham BT; Nguyen KD; Le BT; Nguyen TT; Nguyen ST
BMC Res Notes; 2023 Nov; 16(1):317. PubMed ID: 37932802
[TBL] [Abstract][Full Text] [Related]
22. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
Ji J; Liu L; Jiang F; Wen X; Zhang Y; Li S; Lou J; Wang Y; Liu N; Guo Q; Jia Y; Gao C
J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis.
Liu S; Sun L; Yao L; Zhu H; Diao Y; Wang M; Xing H; Lau WY; Guan M; Pawlik TM; Shen F; Xu M; Tong X; Yang T
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079006
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection.
Truong BX; Yano Y; VAN VT; Seo Y; Nam NH; Trach NK; Utsumi T; Azuma T; Hayashi Y
Biomed Rep; 2013 Jan; 1(1):122-128. PubMed ID: 24648907
[TBL] [Abstract][Full Text] [Related]
25. Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions.
Hamzah N; Kassim NK; Omar J; Abdullah MS; Lee YY
PeerJ; 2023; 11():e15988. PubMed ID: 37780370
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
28. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
29. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma.
Jang TY; Dai CY
Medicine (Baltimore); 2022 Sep; 101(39):e30936. PubMed ID: 36181046
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
31. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
32. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
[TBL] [Abstract][Full Text] [Related]
33. Validation of a novel model for the early detection of hepatocellular carcinoma.
Hemken PM; Sokoll LJ; Yang X; Dai J; Elliott D; Gawel SH; Lucht M; Feng Z; Marrero JA; Srivastava S; Chan DW; Davis GJ
Clin Proteomics; 2019; 16():2. PubMed ID: 30675135
[TBL] [Abstract][Full Text] [Related]
34. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology.
Caviglia GP; Ciruolo M; Abate ML; Carucci P; Rolle E; Rosso C; Olivero A; Troshina G; Risso A; Nicolosi A; Ribaldone DG; Armandi A; Tandoi F; Saracco GM; Bugianesi E; Ciancio A; Gaia S
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142893
[TBL] [Abstract][Full Text] [Related]
35. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation.
Si YQ; Wang XQ; Fan G; Wang CY; Zheng YW; Song X; Pan CC; Chu FL; Liu ZF; Lu BR; Lu ZM
Infect Agent Cancer; 2020 Nov; 15(1):70. PubMed ID: 33292429
[TBL] [Abstract][Full Text] [Related]
36. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
Hu RZ; Zhao SQ; Shen B; Guo GB
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
[No Abstract] [Full Text] [Related]
38. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
39. Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort.
Li T; Li H; Wang A; Su X; Zhao J; Cui Y; Liu J; Hu J
Cancer Manag Res; 2019; 11():9379-9386. PubMed ID: 31807067
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
